Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Fallopian Tube Neoplasms 3Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Ovarian Epithelial 2Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Sarcoma 1Recurrence 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Chondrosarcoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × birinapant × Clear all
NCT01188499 2016-05-30

Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors

TetraLogic Pharmaceuticals

Phase 1/2 Completed
176 enrolled 13 charts
Tumor-Agnostic

Neoplasms

NCT00993239 2016-03-03

Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

TetraLogic Pharmaceuticals

Phase 1 Completed
50 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡